Click here to get full coverage on Warrant vote could unlock $8.7M for Theriva Biologics (TOVX) - Stock Titan

Warrant vote could unlock $8.7M for Theriva Biologics (TOVX)  Stock Titan

Warrant vote could unlock $8.7M for Theriva Biologics (TOVX) - Stock Titan

Click here to get full coverage on Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo

Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1  Moomoo

Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo

Click here to get full coverage on TOVX Should I Buy - Intellectia AI

TOVX Should I Buy - Intellectia AI

Click here to get full coverage on Theriva Biologics (TOVX) Set to Present New Clinical Data at AAC - GuruFocus

Theriva Biologics (TOVX) Set to Present New Clinical Data at AAC  GuruFocus

Theriva Biologics (TOVX) Set to Present New Clinical Data at AAC - GuruFocus

Click here to get full coverage on Theriva Biologics: Q1 Earnings Snapshot - WKYC

Theriva Biologics: Q1 Earnings Snapshot  WKYC

Theriva Biologics: Q1 Earnings Snapshot - WKYC

Click here to get full coverage on Why Is Theriva Stock Gaining Monday? - Benzinga

Why Is Theriva Stock Gaining Monday?  Benzinga

Why Is Theriva Stock Gaining Monday? - Benzinga

Click here to get full coverage on Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - ChartMill

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results  ChartMill

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - ChartMill

Click here to get full coverage on Theriva Biologics (TOVX) price target decreased by 37.50% to 2.55 - MSN

Theriva Biologics (TOVX) price target decreased by 37.50% to 2.55  MSN

Theriva Biologics (TOVX) price target decreased by 37.50% to 2.55 - MSN

Click here to get full coverage on Pancreatic cancer study finds VCN-01 benefits patients with liver spread - Stock Titan

Pancreatic cancer study finds VCN-01 benefits patients with liver spread  Stock Titan

Pancreatic cancer study finds VCN-01 benefits patients with liver spread - Stock Titan

Click here to get full coverage on Theriva Biologics (NYSE American: TOVX) posts Q1 loss, flags going concern risk - Stock Titan

Theriva Biologics (NYSE American: TOVX) posts Q1 loss, flags going concern risk  Stock Titan

Theriva Biologics (NYSE American: TOVX) posts Q1 loss, flags going concern risk - Stock Titan

Click here to get full coverage on Theriva Biologics (NYSE: TOVX) narrows Q1 loss and advances VCN-01 toward pivotal trials - Stock Titan

Theriva Biologics (NYSE: TOVX) narrows Q1 loss and advances VCN-01 toward pivotal trials  Stock Titan

Theriva Biologics (NYSE: TOVX) narrows Q1 loss and advances VCN-01 toward pivotal trials - Stock Titan

Click here to get full coverage on Theriva pushes pancreatic cancer drug VCN-01 toward Phase 3 - Stock Titan

Theriva pushes pancreatic cancer drug VCN-01 toward Phase 3  Stock Titan

Theriva pushes pancreatic cancer drug VCN-01 toward Phase 3 - Stock Titan

Click here to get full coverage on [8-K] Theriva Biologics, Inc. Reports Material Event - Stock Titan

[8-K] Theriva Biologics, Inc. Reports Material Event  Stock Titan

[8-K] Theriva Biologics, Inc. Reports Material Event - Stock Titan

Click here to get full coverage on Gut-targeted SYN-020 licensed to treat metabolic and inflammatory disease - Stock Titan

Gut-targeted SYN-020 licensed to treat metabolic and inflammatory disease  Stock Titan

Gut-targeted SYN-020 licensed to treat metabolic and inflammatory disease - Stock Titan

Click here to get full coverage on Theriva Biologics (NYSE: TOVX) gains FDA alignment on pivotal VCN-01 Phase 3 in metastatic PDAC - Stock Titan

Theriva Biologics (NYSE: TOVX) gains FDA alignment on pivotal VCN-01 Phase 3 in metastatic PDAC  Stock Titan

Theriva Biologics (NYSE: TOVX) gains FDA alignment on pivotal VCN-01 Phase 3 in metastatic PDAC - Stock Titan

Click here to get full coverage on Theriva Biologics (NYSE American: TOVX) resets vote on 16,184,560 warrant shares - Stock Titan

Theriva Biologics (NYSE American: TOVX) resets vote on 16,184,560 warrant shares  Stock Titan

Theriva Biologics (NYSE American: TOVX) resets vote on 16,184,560 warrant shares - Stock Titan

Click here to get full coverage on Cancer drug developer Theriva inks SYN-020 deal up to $38M - Stock Titan

Cancer drug developer Theriva inks SYN-020 deal up to $38M  Stock Titan

Cancer drug developer Theriva inks SYN-020 deal up to $38M - Stock Titan

Click here to get full coverage on Theriva Biologics (TOVX) Receives Upgrade from Maxim Group | TOV - GuruFocus

Theriva Biologics (TOVX) Receives Upgrade from Maxim Group | TOV  GuruFocus

Theriva Biologics (TOVX) Receives Upgrade from Maxim Group | TOV - GuruFocus

Click here to get full coverage on $4.0M Gross Proceeds: Theriva Biologics' Warrant Inducement Issues 14.72M New Warrants - Stock Titan

$4.0M Gross Proceeds: Theriva Biologics' Warrant Inducement Issues 14.72M New Warrants  Stock Titan

$4.0M Gross Proceeds: Theriva Biologics' Warrant Inducement Issues 14.72M New Warrants - Stock Titan

Click here to get full coverage on Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - ChartMill

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting  ChartMill

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - ChartMill

Click here to get full coverage on Theriva Biologics (TOVX) Advances Phase 3 Clinical Trial Plans f - GuruFocus

Theriva Biologics (TOVX) Advances Phase 3 Clinical Trial Plans f  GuruFocus

Theriva Biologics (TOVX) Advances Phase 3 Clinical Trial Plans f - GuruFocus

Click here to get full coverage on TOVX Theriva Biologics Analysis VCN-01 Clinical Potential & Financial Risk $TOVX #TOVX #stockmarket (CG2innXQSF) - Fathom Journal

TOVX Theriva Biologics Analysis VCN-01 Clinical Potential & Financial Risk $TOVX #TOVX #stockmarket (CG2innXQSF)  Fathom Journal

TOVX Theriva Biologics Analysis VCN-01 Clinical Potential & Financial Risk $TOVX #TOVX #stockmarket (CG2innXQSF) - Fathom Journal

Click here to get full coverage on 4/20/2026 Market Update - Winners: ENVB, TOVX, CMND - Losers: PASG, CTNT, FCHL - S&P 500: -0.2% - Trefis

4/20/2026 Market Update - Winners: ENVB, TOVX, CMND - Losers: PASG, CTNT, FCHL - S&P 500: -0.2%  Trefis

4/20/2026 Market Update - Winners: ENVB, TOVX, CMND - Losers: PASG, CTNT, FCHL - S&P 500: -0.2% - Trefis

Click here to get full coverage on Theriva Biologics, Inc. 1Q 2026: Revenue $300K, Net income ($2.04M), EPS ($0.05) — 10-Q Summary - TradingView

Theriva Biologics, Inc. 1Q 2026: Revenue $300K, Net income ($2.04M), EPS ($0.05) — 10-Q Summary  TradingView

Theriva Biologics, Inc. 1Q 2026: Revenue $300K, Net income ($2.04M), EPS ($0.05) — 10-Q Summary - TradingView

Click here to get full coverage on Theriva Biologics (TOVX) Stock Jumps 63% After Pancreatic Cancer Trial Data Drops at AACR - MEXC

Theriva Biologics (TOVX) Stock Jumps 63% After Pancreatic Cancer Trial Data Drops at AACR  MEXC

Theriva Biologics (TOVX) Stock Jumps 63% After Pancreatic Cancer Trial Data Drops at AACR - MEXC

Click here to get full coverage on Theriva Biologics aligns with FDA on Phase 3 VCN-01 design for metastatic PDAC - TradingView

Theriva Biologics aligns with FDA on Phase 3 VCN-01 design for metastatic PDAC  TradingView

Theriva Biologics aligns with FDA on Phase 3 VCN-01 design for metastatic PDAC - TradingView

Click here to get full coverage on TOVX Surges on Thin Volume, Testing 60-Day High Without Confirmation - Bitget

TOVX Surges on Thin Volume, Testing 60-Day High Without Confirmation  Bitget

TOVX Surges on Thin Volume, Testing 60-Day High Without Confirmation - Bitget

Click here to get full coverage on Why Is Theriva Biologics Stock Gaining Monday? - Benzinga

Why Is Theriva Biologics Stock Gaining Monday?  Benzinga

Why Is Theriva Biologics Stock Gaining Monday? - Benzinga

Click here to get full coverage on Theriva Biologics stock soars after EMA backs Phase 3 trial design - Investing.com

Theriva Biologics stock soars after EMA backs Phase 3 trial design  Investing.com

Theriva Biologics stock soars after EMA backs Phase 3 trial design - Investing.com

Click here to get full coverage on These stocks are the most active in today's session - ChartMill

These stocks are the most active in today's session  ChartMill

These stocks are the most active in today's session - ChartMill

Click here to get full coverage on Theriva™ Biologics Announces Upcoming Presentation of Data - GlobeNewswire

Theriva™ Biologics Announces Upcoming Presentation of Data  GlobeNewswire

Theriva™ Biologics Announces Upcoming Presentation of Data - GlobeNewswire

Click here to get full coverage on Theriva Biologics Provides Response to Unusual Market Action - Yahoo Finance

Theriva Biologics Provides Response to Unusual Market Action  Yahoo Finance

Theriva Biologics Provides Response to Unusual Market Action - Yahoo Finance

Click here to get full coverage on Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo

Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market  Moomoo

Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo

Click here to get full coverage on Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020 - RTTNews

Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020  RTTNews

Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020 - RTTNews

Click here to get full coverage on Theriva Biologics to reschedule stockholder meeting after lack of quorum - Investing.com

Theriva Biologics to reschedule stockholder meeting after lack of quorum  Investing.com

Theriva Biologics to reschedule stockholder meeting after lack of quorum - Investing.com

Click here to get full coverage on Theriva Biologics (TOVX) Comprehensive Review | Theriva Biologics posts 34.6% EPS beat, no revenue - Borrow Rate - Cổng thông tin điện tử tỉnh Lào Cai

Theriva Biologics (TOVX) Comprehensive Review | Theriva Biologics posts 34.6% EPS beat, no revenue - Borrow Rate  Cổng thông tin điện tử tỉnh Lào Cai

Theriva Biologics (TOVX) Comprehensive Review | Theriva Biologics posts 34.6% EPS beat, no revenue - Borrow Rate - Cổng thông tin điện tử tỉnh Lào Cai

Click here to get full coverage on Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. - ChartMill

Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session.  ChartMill

Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. - ChartMill

Click here to get full coverage on Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results - Yahoo Finance

Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results  Yahoo Finance

Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results - Yahoo Finance

Click here to get full coverage on Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data - TipRanks

Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data  TipRanks

Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data - TipRanks

Click here to get full coverage on Theriva Biologics Advances VCN-01 Into Pivotal Phase 3 - TipRanks

Theriva Biologics Advances VCN-01 Into Pivotal Phase 3  TipRanks

Theriva Biologics Advances VCN-01 Into Pivotal Phase 3 - TipRanks

Click here to get full coverage on TOVX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

TOVX Earning Date, Earning Analysis and Earning Prediction  Intellectia AI

TOVX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Click here to get full coverage on TradingKey - TradingKey

TradingKey - TradingKey

Click here to get full coverage on What's going on in today's session - ChartMill

What's going on in today's session  ChartMill

What's going on in today's session - ChartMill

Click here to get full coverage on TOVX Advances Oncology Pipeline with Strategic Licensing and Cli - GuruFocus

TOVX Advances Oncology Pipeline with Strategic Licensing and Cli  GuruFocus

TOVX Advances Oncology Pipeline with Strategic Licensing and Cli - GuruFocus

Click here to get full coverage on Is Theriva Biologics (TOVX) stock breaking out today (Investors Pile In) 2026-04-20 - IPO Watch - Cổng thông tin điện tử tỉnh Lào Cai

Is Theriva Biologics (TOVX) stock breaking out today (Investors Pile In) 2026-04-20 - IPO Watch  Cổng thông tin điện tử tỉnh Lào Cai

Is Theriva Biologics (TOVX) stock breaking out today (Investors Pile In) 2026-04-20 - IPO Watch - Cổng thông tin điện tử tỉnh Lào Cai

Click here to get full coverage on TOVX (Theriva Biologics Inc.) posts narrower than expected Q4 2025 loss, shares rise four percent on upbeat investor sentiment. - Popular Trader Picks - Xã Châu Thành

TOVX (Theriva Biologics Inc.) posts narrower than expected Q4 2025 loss, shares rise four percent on upbeat investor sentiment. - Popular Trader Picks  Xã Châu Thành

TOVX (Theriva Biologics Inc.) posts narrower than expected Q4 2025 loss, shares rise four percent on upbeat investor sentiment. - Popular Trader Picks - Xã Châu Thành

Click here to get full coverage on TOVX Technical Analysis & Price Forecast - Intellectia AI

TOVX Technical Analysis & Price Forecast  Intellectia AI

TOVX Technical Analysis & Price Forecast - Intellectia AI

Click here to get full coverage on josephclaudius - StockInvest.us

josephclaudius - StockInvest.us

Click here to get full coverage on Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - GlobeNewswire

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications  GlobeNewswire

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - GlobeNewswire

Click here to get full coverage on TOVX Theriva Biologics posts stronger than expected Q4 2025 EPS, shares jump nearly 60 percent in today’s trading session. - Trending Volume Leaders - Xã Thanh Hà

TOVX Theriva Biologics posts stronger than expected Q4 2025 EPS, shares jump nearly 60 percent in today’s trading session. - Trending Volume Leaders  Xã Thanh Hà

TOVX Theriva Biologics posts stronger than expected Q4 2025 EPS, shares jump nearly 60 percent in today’s trading session. - Trending Volume Leaders - Xã Thanh Hà

Click here to get full coverage on Gapping stocks in Monday's session - ChartMill

Gapping stocks in Monday's session  ChartMill

Gapping stocks in Monday's session - ChartMill

Click here to get full coverage on MSN Money - MSN

MSN Money - MSN

Click here to get full coverage on TOVX Forecast — Price Prediction for 2026. Should I Buy TOVX? - Intellectia AI

TOVX Forecast — Price Prediction for 2026. Should I Buy TOVX?  Intellectia AI

TOVX Forecast — Price Prediction for 2026. Should I Buy TOVX? - Intellectia AI

Click here to get full coverage on 12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session  Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Click here to get full coverage on TOVX - Price, Charts & Blockchain Insights - Intellectia AI

TOVX - Price, Charts & Blockchain Insights  Intellectia AI

TOVX - Price, Charts & Blockchain Insights - Intellectia AI

Click here to get full coverage on Theriva Biologics, Inc. (TOVX) Files Form 8-K with SEC – Company Details and Exchange Information as of April 2026 - Minichart

Theriva Biologics, Inc. (TOVX) Files Form 8-K with SEC – Company Details and Exchange Information as of April 2026  Minichart

Theriva Biologics, Inc. (TOVX) Files Form 8-K with SEC – Company Details and Exchange Information as of April 2026 - Minichart

Click here to get full coverage on Theriva gets FDA alignment on phase 3 trial design for VCN-01 - Investing.com

Theriva gets FDA alignment on phase 3 trial design for VCN-01  Investing.com

Theriva gets FDA alignment on phase 3 trial design for VCN-01 - Investing.com

Click here to get full coverage on Will Theriva Biologics (TOVX) Stock Grow in 2026 | Price at $0.25, Up 8.09% - Elite Trading Signals - Xã Thanh Hà

Will Theriva Biologics (TOVX) Stock Grow in 2026 | Price at $0.25, Up 8.09% - Elite Trading Signals  Xã Thanh Hà

Will Theriva Biologics (TOVX) Stock Grow in 2026 | Price at $0.25, Up 8.09% - Elite Trading Signals - Xã Thanh Hà

Click here to get full coverage on (TOVX) Forecast — Price Target & Prediction for 2026 - Intellectia AI

(TOVX) Forecast — Price Target & Prediction for 2026  Intellectia AI

(TOVX) Forecast — Price Target & Prediction for 2026 - Intellectia AI

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on TOVX Stock Price, News & Analysis | THERIVA BIOLOGICS - Stock Titan

TOVX Stock Price, News & Analysis | THERIVA BIOLOGICS  Stock Titan

TOVX Stock Price, News & Analysis | THERIVA BIOLOGICS - Stock Titan

Click here to get full coverage on What’s Getting Investors So Excited About TOVX Stock? - Stocktwits

What’s Getting Investors So Excited About TOVX Stock?  Stocktwits

What’s Getting Investors So Excited About TOVX Stock? - Stocktwits

Click here to get full coverage on TOVX Stock Price and Chart — AMEX:TOVX - TradingView

TOVX Stock Price and Chart — AMEX:TOVX  TradingView

TOVX Stock Price and Chart — AMEX:TOVX - TradingView

Click here to get full coverage on What is the current Price Target and Forecast for Theriva Biologics, Inc. (TOVX) - Zacks Investment Research

What is the current Price Target and Forecast for Theriva Biologics, Inc. (TOVX)  Zacks Investment Research

What is the current Price Target and Forecast for Theriva Biologics, Inc. (TOVX) - Zacks Investment Research

Click here to get full coverage on TOVX: Theriva Biologics Downgraded by Maxim Group | TOVX Stock N - GuruFocus

TOVX: Theriva Biologics Downgraded by Maxim Group | TOVX Stock N  GuruFocus

TOVX: Theriva Biologics Downgraded by Maxim Group | TOVX Stock N - GuruFocus

Click here to get full coverage on Synthetic Biologics stock plunges to 52-week low of $2.66 - Investing.com

Synthetic Biologics stock plunges to 52-week low of $2.66  Investing.com

Synthetic Biologics stock plunges to 52-week low of $2.66 - Investing.com

Click here to get full coverage on Can Theriva's PDAC Trial Success and FDA Fast Track Save Its Dwindling Cash Position? - Stock Titan

Can Theriva's PDAC Trial Success and FDA Fast Track Save Its Dwindling Cash Position?  Stock Titan

Can Theriva's PDAC Trial Success and FDA Fast Track Save Its Dwindling Cash Position? - Stock Titan

Click here to get full coverage on Theriva Biologics, Inc. (TOVX) - Zacks Investment Research

Theriva Biologics, Inc. (TOVX)  Zacks Investment Research

Theriva Biologics, Inc. (TOVX) - Zacks Investment Research

Click here to get full coverage on TOVX Stock Price, Quote & Chart | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill

TOVX Stock Price, Quote & Chart | THERIVA BIOLOGICS INC (NYSEARCA:TOVX)  ChartMill

TOVX

Price Chart

Key Statistics

Technicals

About TOVX

Latest News

Warrant vote could unlock $8.7M for Theriva Biologics (TOVX) - Stock Titan

Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo

TOVX Should I Buy - Intellectia AI

Advanced Charts

Top Gainers

Top Losers